AXT 301
Alternative Names: AXT-301Latest Information Update: 26 Feb 2021
At a glance
- Originator AsclepiX Therapeutics
- Class Antineoplastics; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioma; Triple negative breast cancer
Most Recent Events
- 17 Feb 2021 Preclinical trials in Glioma in USA (unspecified route), prior to February 2021 (AsclepiX Therapeutics pipeline, February 2021)
- 17 Feb 2021 Preclinical trials in Triple negative Breast cancer in USA (unspecified route), prior to February 2021 (AsclepiX Therapeutics pipeline, February 2021)